Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 65/100

Failure Rate

16.7%

1 terminated/withdrawn out of 6 trials

Success Rate

66.7%

-19.8% vs industry average

Late-Stage Pipeline

17%

1 trials in Phase 3/4

Results Transparency

0%

0 of 2 completed trials have results

Key Signals

2 recruiting

Enrollment Performance

Analytics

N/A
2(40.0%)
Phase 2
1(20.0%)
Phase 1
1(20.0%)
Phase 4
1(20.0%)
5Total
N/A(2)
Phase 2(1)
Phase 1(1)
Phase 4(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (6)

Showing 6 of 6 trials
NCT06351683Phase 2Terminated

Testing MitoQ on Lower Urinary Tract Symptoms in Older Women With Metabolic Syndrome

Role: collaborator

NCT06243510Not ApplicableEnrolling By Invitation

Comparison of Apixaban Versus Enoxaparin

Role: collaborator

NCT04807894Phase 4Recruiting

Prevention of Recurrent UTI Using Vaginal Testosterone Versus Placebo Placebo

Role: collaborator

NCT07100847Phase 1Recruiting

Periprostatic Neurolysis in Prostate Cancer

Role: collaborator

NCT05111639Completed

Decision Making for Urinary Diversion in Patients With Bladder Cancer

Role: collaborator

NCT01168323Not ApplicableCompleted

Spaced Education to Optimize Prostate Cancer Screening

Role: collaborator

All 6 trials loaded